Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A COMMERCIAL STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO SIX NEW EMPLOYEES AS DESCRIBED BELOW. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THESE AWARDS WERE APPROVED BY NEURONETICS' COMPENSATION COMMITTEE AND MADE AS A MATERIAL INDUCEMENT TO THEIR RESPECTIVE EMPLOYMENT WITH THE COMPANY. IN ALL CASES, VESTING IS SUBJECT TO THE RECIPIENT'S CONTINUED SERVICE WITH THE COMPANY THROUGH THE APPLICABLE VESTING DATE, AND THE AWARDS ARE SUBJECT TO THE TERMS OF THE COMPANY'S 2020 INDUCEMENT INCENTIVE PLAN.

NEURONETICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

MALVERN, PA., AUG. 04, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED THAT KEITH SULLIVAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE ON TUESDAY, AUGUST 12, 2025. THE COMPANY IS SCHEDULED TO PRESENT AT 1:30PM EASTERN TIME THE SAME DAY. THE PRESENTATION WILL BE AVAILABLE VIA THE CONFERENCE PORTAL TO REGISTERED ATTENDEES AND PRESENTING COMPANIES FOR 14 DAYS FOLLOWING THE EVENT. ABOUTNEURONETICS NEURONETICS, INC. BELIEVES THAT MENTAL HEALTH IS AS IMPORTANT AS PHYSICAL HEALTH. AS A GLOBAL LEADER IN NEUROSCIENCE, NEURONETICS IS DELIVERING MORE TREATMENT OPTIONS TO PATIENTS AND PHYSICIANS BY OFFERING EXCEPTIONAL IN-OFFICE TREATMENTS THAT PRODUCE EXTRAORDINARY RESULTS. NEUROSTAR ADVANCED THERAPY IS A NON-DRUG, NONINVASIVE TREATMENT THAT CAN IMPROVE THE QUALITY OF LIFE FOR PEOPLE SUFFERING FROM NEUROHEALTH CONDITIONS WHEN TRADITIONAL MEDICATION HAS NOT HELPED. IN ADDITION TO SELLING THE NEUROSTAR ADVANCED THERAPY SYSTEM AND ASSOCIATED TREATMENT SESSIONS TO CUSTOMERS, NEURONETICS OPERATES GREENBROOK TMS INC. (GREENBROOK) TREATMENT CENTERS ACROSS THE UNITED STATES, OFFERING NEUROSTAR ADVANCED THERAPY FOR THE TREATMENT OF MDD AND OTHER MENTAL HEALTH DISORDERS. NEUROSTAR ADVANCED THERAPY IS THE LEADING TMS TREATMENT FOR MDD IN ADULTS, WITH MORE THAN 7.4 MILLION TREATMENTS DELIVERED, AND IS BACKED BY THE LARGEST CLINICAL DATA SET OF ANY TMS TREATMENT SYSTEM FOR DEPRESSION, INCLUDING THE WORLD'S LARGEST DEPRESSION OUTCOMES REGISTRY. GREENBROOK TREATMENT CENTERS ALSO OFFER SPRAVATO (ESKETAMINE) NASAL SPRAY, A PRESCRIPTION MEDICINE INDICATED FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS AS MONOTHERAPY OR IN CONJUNCTION WITH AN ORAL ANTI

NEURONETICS TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

REAL-WORLD DATA SHOWING NEUROSTAR IS EFFECTIVE IN ADOLESCENTS AND YOUNG ADULTS WITH DEPRESSION FROM THE WORLD'S LARGEST TMS OUTCOMES DATASET REAL-WORLD DATA SHOWING NEUROSTAR IS EFFECTIVE IN ADOLESCENTS AND YOUNG ADULTS WITH DEPRESSION FROM THE WORLD'S LARGEST TMS OUTCOMES DATASET

NEUROSTAR ANNOUNCES NEW PUBLICATION IN JAACAP OPEN HIGHLIGHTING TREATMENT EFFICACY IN DEPRESSED ADOLESCENTS

STEVEN PFANSTIEL, A SEASONED FINANCIAL EXECUTIVE WITH EXTENSIVE MEDICAL TECHNOLOGY AND PHARMACEUTICAL EXPERIENCE, REPLACES STEVE FURLONG AS CHIEF FINANCIAL OFFICER FOLLOWING PREVIOUSLY ANNOUNCED SUCCESSION PROCESS

NEURONETICS APPOINTS NEW CHIEF FINANCIAL OFFICER

MALVERN, PA., JUNE 19, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A COMMERCIAL STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO ONE NEW NON-EXECUTIVE EMPLOYEE AS DESCRIBED BELOW. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THESE AWARDS WERE APPROVED BY NEURONETICS' COMPENSATION COMMITTEE AND MADE AS A MATERIAL INDUCEMENT TO THEIR RESPECTIVE EMPLOYMENT WITH THE COMPANY. IN ALL CASES, VESTING IS SUBJECT TO THE RECIPIENT'S CONTINUED SERVICE WITH THE COMPANY THROUGH THE APPLICABLE VESTING DATE, AND THE AWARDS ARE SUBJECT TO THE TERMS OF THE COMPANY'S 2020 INDUCEMENT INCENTIVE PLAN.

NEUROSTAR, A SILVER SPONSOR AT CTMSS, WILL ALSO PRESENT TWO POSTERS AS PART OF THE COMPANY'S ONGOING COMMITMENT TO CLINICAL INNOVATION AND EXCELLENCE NEUROSTAR, A SILVER SPONSOR AT CTMSS, WILL ALSO PRESENT TWO POSTERS AS PART OF THE COMPANY'S ONGOING COMMITMENT TO CLINICAL INNOVATION AND EXCELLENCE

NEURONETICS ANNOUNCES CLINICAL PRESENCE AT THE 2025 CLINICAL TMS SOCIETY ANNUAL MEETING AND PROGRESS IN GREENBROOK'S PERSONALIZED CARE TRIAL PROGRAM

MALVERN, PA., JUNE 02, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED THAT IT IS SET TO JOIN THE BROAD-MARKET RUSSELL 3000 INDEX AND THE SMALL-CAP RUSSELL 2000 INDEX AT THE CONCLUSION OF THE RUSSELL INDEXES ANNUAL RECONSTITUTION, EFFECTIVE AFTER THE US MARKET OPENS ON JUNE 30, 2025.

NEURONETICS SET TO JOIN RUSSELL 2000 AND RUSSELL 3000 INDEXES

MALVERN, PA., MAY 06, 2025 (GLOBE NEWSWIRE) -- NEURONETICS,INC., (NASDAQ: STIM) (THE COMPANY OR NEURONETICS) A VERTICALLY INTEGRATED, COMMERCIAL STAGE, MEDICAL TECHNOLOGY AND HEALTHCARE COMPANY WITH A STRATEGIC VISION OF TRANSFORMING THE LIVES OF PATIENTS WHENEVER AND WHEREVER THEY NEED HELP, WITH THE LEADING NEUROHEALTH THERAPIES IN THE WORLD, TODAY ANNOUNCED ITS FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER OF 2025.

NEURONETICS REPORTS FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS

MALVERN, PA., MAY 05, 2025 (GLOBE NEWSWIRE) -- NEURONETICS, INC. (NASDAQ: STIM), A COMMERCIAL STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON DESIGNING, DEVELOPING, AND MARKETING PRODUCTS THAT IMPROVE THE QUALITY OF LIFE FOR PATIENTS WHO SUFFER FROM NEUROHEALTH DISORDERS, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS OF RESTRICTED STOCK UNITS REPRESENTING A TOTAL OF 4,500 SHARES OF THE COMPANY'S COMMON STOCK (RSUS) TO THREE NEW NON-EXECUTIVE EMPLOYEES. IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4), THESE AWARDS WERE APPROVED BY NEURONETICS' COMPENSATION COMMITTEE AND MADE AS MATERIAL INDUCEMENTS TO THEIR RESPECTIVE EMPLOYMENT WITH THE COMPANY.

POLICY UPDATE INCREASES ACCESS FOR MILLIONS COVERED BY EVERNORTH HEALTH SERVICES POLICY UPDATE INCREASES ACCESS FOR MILLIONS COVERED BY EVERNORTH HEALTH SERVICES

Neuronetics, Inc.

STIM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Neuronetics, Inc.

STIM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

STIM